AstraZeneca Acquires Fusion Pharmaceuticals for $2.4B, FDA Approves First MASH Treatment, and More News Highlights From March 2024

Companies inked notable high-profile transactions in March 2024, including AbbVie's purchase of Landos Biopharma for $137.5M, AstraZeneca's $2.4B acquisition of Fusion Pharmaceuticals, and its subsequent deal to buy Amolyt Pharma for up to $1.05B. The FDA gave thumbs up to the first treatment for metabolic dysfunction–associated steatohepatitis (MASH), which marks a leap forward in liver disease management. In parallel, expectations are high for the approval of Xcovery's ALK inhibitor, ensartinib. Praxis Precision Medicines also made headlines with PRAX-628, a next-generation oral NaV modulator, which showed promising anti-seizure efficacy in a Ph. IIa trial. This article highlights details on these and other drug discovery news stories that you may have missed from March 2024.